The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Cell Lines: A Tool for In Vitro Drug Metabolism Studies
Abstract
Primary cultured hepatocytes are a valuable in vitro model for drug metabolism studies. However, their widespread use is greatly hindered by the scarcity of suitable human liver samples. Moreover, the well-known in vitro phenotypic instability of hepatocytes, the irregular availability of fresh human liver for cell harvesting purposes, and the high batch-to-batch functional variability of hepatocyte preparations obtained from different human liver donors, seriously complicate their use in routine testing. To overcome these limitations, different cell line models have been proposed for drug metabolism screening. Human liver-derived cell lines would be ideal models for this purpose given their availability, unlimited life-span, stable phenotype, and the fact that they are easy to handle. However, the human hepatoma cells currently used (i.e. HepG2, Mz-Hep-1) show negligible levels of drug-metabolizing and do not constitute a real alternative to primary hepatocytes. Different strategies have been proposed to generate metabolically competent immortalized hepatocytes (transformation of human hepatocytes with plasmids encoding immortalizing genes, hepatocyte-like cells derived from stem cells, cell lines generated from transgenic animals, hepatocyte/hepatoma hydrid cells). Moreover, recombinant models heterologously expressing P450 enzymes in different host cells have been developed and successfully used in drug metabolism testing. In addition, new strategies have recently been explored to upregulate the expression of drug-metabolizing enzymes in cell lines of a human origin (i.e. transfection with expression vectors encoding key hepatic transcription factors). Among metabolic-based drug-drug interactions, P450 inhibition seems to be the most important. A major application of recombinant models expressing a single P450 is the screening of potential enzyme inhibitors. Therefore, pharmaceutical companies increasingly make use of cell lines to speed up the selection of new drugs with favourable pharmacokinetic and metabolic properties.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Human Hepatocytes in Primary Culture: The Choice to Investigate Drug Metabolism in Man
Gomez-Lechon, M., Donato, M., Castell, J., & Jover, R. (2004) · Current Drug Metabolism · doi:10.2174/1389200043335414 · Cited by 252
Self-citationHuman hepatocytes as a tool for studying toxicity and drug metabolism
Gomez-Lechon, M., Donato, M., Castell, J., & Jover, R. (2003) · Current Drug Metabolism · doi:10.2174/1389200033489424 · Cited by 242
Self-citationIn Vitro Methods in Pharmaceutical Research
(1997) · Elsevier eBooks · doi:10.1016/b978-0-12-163390-5.x5000-5 · Cited by 149
Grant, M. H., Duthie, S. J., Gray, A. G., & Burke, M. D. (1988) · Biochemical Pharmacology · doi:10.1016/0006-2952(88)90103-7 · Cited by 144
Schoonen, W. G. E. J., de Roos, J. A. D. M., Westerink, W. M. A., & Débiton, E. (2005) · Toxicology in Vitro · doi:10.1016/j.tiv.2005.01.002 · Cited by 133
Yoshitomi, S., Ikemoto, K., Takahashi, J., Miki, H., Namba, M., & Asahi, S. (2001) · Toxicology in Vitro · doi:10.1016/s0887-2333(01)00011-x · Cited by 113
Yanai, N., Suzuki, M., & Obinata, M. (1991) · Experimental Cell Research · doi:10.1016/0014-4827(91)90478-d · Cited by 107
Glatt, H. R., Gemperlein, I., Setiabudi, F., Platt, K. L., & Oesch, F. (1990) · Mutagenesis · doi:10.1093/mutage/5.3.241 · Cited by 102
Cell-based high-throughput bioassays to assess induction and inhibition of CYP1A enzymes
Yueh, M., Kawahara, M. S., & Raucy, J. L. (2004) · Toxicology in Vitro · doi:10.1016/j.tiv.2004.10.003 · Cited by 66
Yueh, M., Kawahara, M. S., & Raucy, J. L. (2004) · Drug Metabolism and Disposition · doi:10.1124/dmd.104.001594 · Cited by 63
Cited by
Godoy, P., Hewitt, N. J., Albrecht, U., Andersen, M. E., Ansari, N., Bhattacharya, S., Bode, J. G., Bolleyn, J., Borner, C., Böttger, J., et al. (2013) · Archives of Toxicology · doi:10.1007/s00204-013-1078-5 · Cited by 1,280
Self-citationGerets, H. H. J., Tilmant, K., Gerin, B., Chanteux, H., Depelchin, B. O., Dhalluin, S., & Atienzar, F. A. (2012) · Cell Biology and Toxicology · doi:10.1007/s10565-011-9208-4 · Cited by 698
Inhibition and induction of human cytochrome P450 enzymes: current status
Pelkonen, O., Turpeinen, M., Hakkola, J., Honkakoski, P., Hukkanen, J., & Raunio, H. (2008) · Archives of Toxicology · doi:10.1007/s00204-008-0332-8 · Cited by 569
Astashkina, A., Mann, B., & Grainger, D. W. (2012) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2012.01.001 · Cited by 424
Guo, L., Dial, S., Shi, L., Branham, W., Liu, J., Fang, J.-L., Green, B., Deng, H., Kaput, J., & Ning, B. (2011) · Drug Metabolism and Disposition · doi:10.1124/dmd.110.035873 · Cited by 348
Culture and Functional Characterization of Human Hepatoma HepG2 Cells
Donato, M. T., Tolosa, L., & Gómez-Lechón, M. J. (2015) · Methods in Molecular Biology · doi:10.1007/978-1-4939-2074-7_5 · Cited by 331
Self-citationCompetency of different cell models to predict human hepatotoxic drugs
Gómez-Lechón, M. J., Tolosa, L., Conde, I., & Donato, M. T. (2014) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2014.967680 · Cited by 199
Self-citationA critical perspective on 3D liver models for drug metabolism and toxicology studies
Serras, A. S., Rodrigues, J. S., Cipriano, M., Rodrigues, A. V., Oliveira, N. G., & Miranda, J. P. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.626805 · Cited by 138
Models of Drug Induced Liver Injury (DILI)—Current Issues and Future Perspectives
Kuna, L., Bozic, I., Kizivat, T., Bojanic, K., Mrso, M., Kralj, E., Smolic, R., Wu, G. Y., & Smolic, M. (2018) · Current Drug Metabolism · doi:10.2174/1389200219666180523095355 · Cited by 127
Microengineered Liver Tissues for Drug Testing
Khetani, S. R., Berger, D. R., Ballinger, K. R., Davidson, M. D., Lin, C., & Ware, B. R. (2015) · SLAS Technology · doi:10.1177/2211068214566939 · Cited by 116
“Several hepatic cell lines have been used for drug development, including HepG2, HepaRG, Fa2N-4, and others.(8,33,34) While providing for a reproducible and nearly infinite source of liver cells for building initial iterations of engineered devices as well as for drug testing, cell lines are widely accepted to lack th…”
MethodIdentification and molecular docking of antioxidant peptides from hemp seed protein hydrolysates
Gao, J., Li, T., Chen, D., Gu, H., & Mao, X. (2021) · LWT · doi:10.1016/j.lwt.2021.111453 · Cited by 106
Xuan, J., Chen, S., Ning, B., Tolleson, W. H., & Guo, L. (2016) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2015.10.009 · Cited by 103
In Vitro Models for the Study of Non-Alcoholic Fatty Liver Disease
C. Chavez-Tapia, N., Rosso, N., & Tiribelli, C. (2011) · Current Medicinal Chemistry · doi:10.2174/092986711794940842 · Cited by 86
“non neoplastic) and the method for immortalization which may introduce variations in some metabolic functions that need to be considered in interpreting the results [10].”
Liver three-dimensional cellular models for high-throughput chemical testing
Yang, S., Ooka, M., Margolis, R. J., & Xia, M. (2023) · Cell Reports Methods · doi:10.1016/j.crmeth.2023.100432 · Cited by 75
Advances in Engineered Liver Models for Investigating Drug-Induced Liver Injury
Lin, C., & Khetani, S. R. (2016) · BioMed Research International · doi:10.1155/2016/1829148 · Cited by 66
Microfluidic Liver-on-a-Chip for Preclinical Drug Discovery
Fu, J., Qiu, H., & Tan, C. S. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15041300 · Cited by 42
A comparison of hepato-cellular in vitro platforms to study CYP3A4 induction
Bulutoglu, B., Rey-Bedón, C., Mert, S., Tian, L., Jang, Y.-Y., Yarmush, M. L., & Usta, O. B. (2020) · PLOS ONE · doi:10.1371/journal.pone.0229106 · Cited by 41
LC-MS Untargeted Metabolomic Analysis of Drug-Induced Hepatotoxicity in HepG2 Cells
García‐Cañaveras, J. C., Jiménez, N., Gómez‐Lechón, M. J., Castell, J. V., Donato, M. T., & Lahoz, A. (2015) · ELECTROPHORESIS · doi:10.1002/elps.201500095 · Cited by 41
Self-citationChiang, T.-S., Yang, K.-C., Chiou, L.-L., Huang, G.-T., & Lee, H.-S. (2014) · PLoS ONE · doi:10.1371/journal.pone.0094885 · Cited by 17
1,5-Benzodiazepin-2(3H)-ones: In Vitro Evaluation as Antiparkinsonian Agents
Ortíz de Zárate, A., Pérez-Torralba, M., Bonet Isidro, I., López, C., Claramunt, R. M., Martínez-Casanova, D., Sánchez-Vera, I., Jiménez-González, J., & Lavandera, J. L. (2021) · Antioxidants · doi:10.3390/antiox10101584 · Cited by 11
“On the other hand, HepG2 is the most well recognized and widely studied human hepatoma cell line as an in vitro model for chemical risk assessment in drug discovery studies for cytotoxicity, hepatotoxicity, metabolism, and genotoxicity [142,143].”
Background
Metadata
- Authors
- Gomez-Lechon, M., Donato, M., Lahoz, A., & Castell, J.
- Venue
- Current Drug Metabolism
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2008-01-01
- Volume
- 9
- Issue
- 1
- Pages
- 1-11
- ISSN
- 1389-2002 (ISSN-L)
- OpenAlex
- W2141254815
- Cited by
- 300
- References
- 14
- FWCI
- 12.97
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.